News

Cannabis has been shown to have efficacy across a range of different medical conditions, from anxiety to epilepsy, chronic pain, arthritis, insomnia, and chemotherapy-induced nausea. Which formulation is best will depend on the condition being treated and the needs of the patient. What is best for one person may be ineffective or inappropriate for someone else.

Upholding rigorous quality standards is only made possible by strong systems and processes. Innovative tech is making this a reality for Canngea and the global cannabis industry.

NEWS RELEASE – Canngea Pty Ltd and Spring Sciences Australia Pty. Ltd. (“SSA”) are pleased to announce the companies have entered a Supply Agreement.

Ora Pharm is the first New Zealand company in the Medicinal Cannabis space to export a branded product to an international market.

There are two significant differences between recreational and medicinal cannabis (prescription and over the counter)

Given human’s recreational experience with cannabis, why are the Australian and other governments insisting on clinical trials before they register medicinal cannabis products? Well, it turns out that there is still a huge amount we don’t know about it as a medicine.

It has been officially announced today that New Zealand medicinal cannabis company, Ora Pharm, has struck an exciting partnership deal with Canngea, one of Australia’s leading medical cannabis manufacturing and distribution companies.

Canngea Secures Supply Agreement with ECS Botanics

Check out Canngea Commercial Director Martin Bryden and Science Director Dr Nial Wheate in their interview with UnderJungle host Joshua Sauvage.

Canngea exists to bridge the gap between ancient and contemporary medicine for a better quality of life.